Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabwell Says Nectin-4 ADC Posts Positive Results in Solid Tumor Cancers

publication date: Apr 7, 2023

Shanghai Mabwell reported its Nectin-4 targeted site-specific ADC candidate demonstrated promising clinical results in a China Phase II trial that enrolled patients with solid tumor cancers. The company said preliminary data show positive efficacy with a good safety profile. Developed with site specific conjugate technology, 9MW2821 is China's first Nectin-4 targeted ADC to start clinical trials. In preliminary data, the candidate produced an ORR of 50% and DCT of 100% in urothelial and cervical carcinoma patients, two of the more than ten solid tumor cancers targeted by the Nectin-4 ADC. More details....

Stock Symbol: (SHA: 688062)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital